OXURION announces its presence at the Paris SmallCap event on March 28, 2024.
March 25 2024 - 1:10PM
OXURION announces its presence at the
Paris SmallCapevent on March 28,
2024.
Leuven, BELGIUM - March 25, 2024 - 7:00 p.m, Oxurion NV
(Euronext Brussels : OXUR), a Leuven-based biopharmaceutical
company, is pleased to announce its participation in the SmallCap
event, scheduled for March 28 in Paris.
The event, organized in key cities such as Paris, London,
Frankfurt and Amsterdam, serves as a platform for bringing together
European issuers and a wider network of institutional investors and
family offices across Europe.
Pascal Ghoson, CEO of Oxurion, expresses his enthusiasm: "Our
participation in this event is an opportunity. In fact. This will
be an ideal place for us to unveil our future growth strategy and
highlight the strengths that make us unique."
For more information on the event, please visit their
website.
About Oxurion Oxurion
(Euronext Brussels: OXUR) is committed to the
development of next-generation standard ophthalmic therapies for
the treatment of retinal diseases. Oxurion's head office is in
Leuven. Further information is available at www.oxurion.com.
Important information on forward-looking
statements
Certain statements contained in this press
release may be considered as “forward-looking". These forward
looking statements are based on current expectations and are
therefore subject to various risks and uncertainties. The company
therefore cannot guarantee that these forward-looking statements
will materialise and does not undertake to update or revise them,
whether as a result of new information, future events or for any
other reason. Additional information on the risks and uncertainties
affecting the company and other factors that could cause actual
results to differ materially from forward-looking statements is
included in the company's annual report. This press release does
not constitute an offer or an invitation to sell or buy securities
or assets of Oxurion in any jurisdiction. No Oxurion securities may
be offered or sold in the United States without registration under
the 1933 U.S. Securities Act as amended, or pursuant to a waiver of
such Act, and in accordance with all applicable state securities
laws.
Contacts :
OXURION NVPascal
Ghosonpascal.ghoson@oxurion.com |
Oxurion NV (EU:OXUR)
Historical Stock Chart
From Jan 2025 to Feb 2025
Oxurion NV (EU:OXUR)
Historical Stock Chart
From Feb 2024 to Feb 2025